Search
N2-[(benzyloxy)carbonyl]-n1-[(3S)-1-cyanopyrrolidin-3-yl]-l-leucinamide
go.drugbank.com/drugs/DB03456ExperimentalIt is known to target cathepsin K.
SYNB1353
go.drugbank.com/drugs/DB17666InvestigationalIt is designed to consume methionine in the gastrointestinal tract to prevent its absorption and conversion into homocysteine.[L45983]
1D09C3
go.drugbank.com/drugs/DB05121Experimental1D09C3, a monoclonal antibody against lymphoid cancers, is an anti-MHC (major histocompatibility complex) class II monoclonal antibody. The antibody was isolated in collaboration with MorphoSys from its HuCAL(R) library of human antibodi...
Atl146e
go.drugbank.com/drugs/DB05191InvestigationalATL146e is an anti-inflammatory compounds which is an agonist of A2A adenosine receptors.
Mosedipimod
go.drugbank.com/drugs/DB12592InvestigationalMosedipimod has been used in trials studying the supportive care and treatment of Chemotherapy-induced Neutropenia.
CYP-001
go.drugbank.com/drugs/DB15739InvestigationalCYP-001 is a mesenchymoangioblast (MCA)-derived mesenchymal stem cell (MSC) therapy that originates from the mesoderm. When activated with fibroblast growth factor-2 (FGF-2), MCAs create colonies with specific phenotypes. These cells are...
Antilymphocyte immunoglobulin (horse)
go.drugbank.com/drugs/DB09312ApprovedInvestigationalIt is formed by inoculating a horse with an antigen (human thymoyctes) which then induces the horse immune system's B-lymphocytes to produce IgG immunoglobulins specific for that antigen.
Gataparsen
go.drugbank.com/drugs/DB05141InvestigationalLY2181308 is investigated in clinical trials for treating solid tumors. LY2181308 is a solid. LY2181308 is directed against a molecular target called survivin. LY2181308 is known to target baculoviral IAP repeat-containing protein 5. LY2...
Eldecalcitol
go.drugbank.com/drugs/DB05295InvestigationalEldecalcitol (ED-71), a vitamin D analog, is a more potent inhibitor of bone resorption than alfacalcidol in an estrogen-deficient rat model of osteoporosis. Eldecalcitol, effectively and safely increased lumbar and hip bone mineral dens...
TBC-3711
go.drugbank.com/drugs/DB05407InvestigationalTBC3711 is a next-generation endothelin antagonist that is being studied through oral and intravenous formulations by Encysive Pharmaceuticals.